Management of Melanoma in Patients with Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is the most prevalent lymphoid malignancy in the United States, with approximately 140,000 people living with the disease [1]. Immune dysfunction is an early and clinically important complication of CLL [2]. Patients with CLL are at significantly increased risk of skin cancer including melanoma, and have a ~2-fold increased risk of mortality from these second malignancies compared to patients without a preceding diagnosis of CLL [3 –7]. (Source: Leukemia Research)
Source: Leukemia Research - July 6, 2018 Category: Hematology Authors: William J. Archibald, Philip J. Meacham, AnnaLynn M. Williams, Andrea M. Baran, Adrienne I. Victor, Paul M. Barr, Deepak M. Sahasrahbudhe, Clive S. Zent Tags: Research paper Source Type: research
Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia
Induction chemotherapy results in high remission rate in high risk (HR) and very high risk (VHR) childhood acute lymphoblastic leukemia (ALL), but is associated with significant morbidity [1,2]. HR B-ALL is defined as: white blood cell count (WBC) ≥50,000/µL or age ≥10 years (National Cancer Institute (NCI) criteria) at presentation, or/and central nervous system (CNS) positive leukemia, or testicular leukemia [3–5]. Patients who are>13 years or experience induction failures; and/or if the leukemia blasts harbor mixed-lineage leukemia gene (MLL) rearrangements or intrachromosomal amplification of chromosome 21 (iAMP...
Source: Leukemia Research - July 2, 2018 Category: Hematology Authors: Kasper Warrick, Sandra K. Althouse, April Rahrig, Joy Rupenthal, Sandeep Batra Tags: Research paper Source Type: research
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
Therapies for the Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), have generally been palliative and not curative. The only potentially curative therapy remains allogeneic hematopoietic stem-cell transplantation, but widespread application in patients with MPN is limited by factors that include disease stage, comorbidities, and donor availability [1,2]. (Source: Leukemia Research)
Source: Leukemia Research - July 2, 2018 Category: Hematology Authors: J. Berdeja, F. Palandri, M.R. Baer, D. Quick, J.J. Kiladjian, G. Martinelli, A. Verma, O. Hamid, R. Walgren, C. Pitou, P.L. Li, A.T. Gerds Tags: Research paper Source Type: research
Editorial Board
(Source: Leukemia Research)
Source: Leukemia Research - July 1, 2018 Category: Hematology Source Type: research
Morphologic Dysplasia in Myelodysplastic Syndromes: How accurate are morphologists?
In the absence of an increased % of blasts (5-19%) and accepted cytogenetic findings [(-7, del(7),del(5q), isochrome 17q or l(17p), -13 or del(13q), (-11), and rarer losses and translocations] [1] a diagnosis of Myelodysplastic Syndromes (MDS) can still be made in the presence of cytopenias and morphologic dysplasia ( “abnormal growth or development of cells”) [2] that persists for several months. (Source: Leukemia Research)
Source: Leukemia Research - June 21, 2018 Category: Hematology Authors: John M. Bennett Source Type: research
Should more MDS patients be treated with immune-suppression?
Despite the fact that the emergence of neoplastic hematopoietic clones are the central pathophysiological events in MDS [1], many other mechanisms are required to ensure the survival, proliferation and predominance of these clones over normal hematopoiesis. The need for these accessory mechanisms is attested by the recent findings that clonal hematopoesis per se is not sufficient to generate MDS [2]. MDS clones are aided in their survival by changes in bone marrow stroma [3] and immune dysregulation, both of which are likely to be generated by the MDS clone itself [4]. (Source: Leukemia Research)
Source: Leukemia Research - June 19, 2018 Category: Hematology Authors: Antonio Almeida Source Type: research
Economic Burden of Elderly Patients With Acute Myeloid Leukemia Treated in Routine Clinical Care in the United States
Acute myeloid leukemia (AML) is a heterogeneous hematologic neoplasm characterized by clonal proliferation of myeloid precursor cells in the peripheral blood, bone marrow, and/or other tissues [1]. There are an estimated 21,000 new cases of AML diagnosed annually in the United States (US), with the incidence steadily increasing at about 5% per year [2,3]. AML is generally a disease affecting elderly patients, with a median age at diagnosis of 69 years [4]. The overall prognosis for AML is poor, with less than 30% of patients surviving 5 years from diagnosis; however, outcomes vary according to multiple prognostic factors, ...
Source: Leukemia Research - June 16, 2018 Category: Hematology Authors: Jill A. Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Augustina Ogbonnaya, Mike Eaddy, Robert J. Fram, Douglas V. Faller, Vamsi Kota Tags: Research paper Source Type: research
Cytoplasmic CD3 expression in Infant Acute Megakaryoblastic Leukemia: a new ambiguous lineage subtype?
We report four pediatric acute leukemia (AL) cases (prevalence: 0.18%) with megakaryoblasts co-expressing the T-specific antigen CD3 (cytoplasmic), together with a very homogeneous antigen profile of immature cells and other lymphoid traits. (Source: Leukemia Research)
Source: Leukemia Research - June 15, 2018 Category: Hematology Authors: Jorge Gabriel Rossi, Patricia Rubio, Cristina N. Alonso, Andrea R. Bernasconi, Elisa O. Sajaroff, Jorge Digiorge, Edgardo Baialardo, Silvia Eandi-Eberle, Myriam Guitter, Angelica Fernandez-Barbieri, Raquel Mitchell, Maria Sara Felice Tags: Letter to the Editor Source Type: research
Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: portrait of a rare clinical entity
According to the WHO classification, ‘other iatrogenic immunodeficiency-associated lymphoproliferative disorders’ (LPD) are lymphoid proliferations or lymphomas arising in patients treated with immunosuppressive drugs for autoimmune diseases or disorders other than the post-transplant setting [1]. LPD that develop in patients with inflammatory bowel disease (IBD) as a background are included in this category. In 2002, Kandiel et al. performed a meta-analysis demonstrating a fourfold increased risk of lymphoma in the subgroup of IBD patients treated with azathioprine and/or 6-mercaptopurine (6-MP), compared to the risk ...
Source: Leukemia Research - June 13, 2018 Category: Hematology Authors: Merav Barzilai, Aaron Polliack, Irit Avivi, Yair Herishanu, Ron Ram, Catherine Tang, Chava Perry, Nadav Sarid Source Type: research
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies
Myelodysplastic syndromes (MDS) are a series of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a propensity to transform to acute myeloid leukemia (AML) [1]. AML is a myeloid malignancy characterized by increased self-renewal, limited differentiation and deregulated proliferation of myeloid blasts. They may cause bone marrow failure and death within months or even weeks if diagnosis and treatment time is delayed. Recent studies showed that demethylating agents 5-azacytidine (AZA) and 5-aza-2-deoxycytidine (decitabine, DAC) may bring substantial survival...
Source: Leukemia Research - June 9, 2018 Category: Hematology Authors: Tingting Pan, Jiaqian Qi, Tao You, Liping Yang, Depei Wu, Yue Han, Li Zhu Source Type: research
Addition of histone deacetylase inhibitors does not improved prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies
Myelodysplastic syndromes (MDS) are a series of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a propensity to transform to acute myeloid leukemia (AML) [1]. AML is a myeloid malignancy characterized by increased self-renewal, limited differentiation and deregulated proliferation of myeloid blasts. They may cause bone marrow failure and death within months or even weeks if diagnosis and treatment time is delayed. Recent studies showed that demethylating agents 5-azacytidine (AZA) and 5-aza-2-deoxycytidine (decitabine, DAC) may bring substantial survival...
Source: Leukemia Research - June 9, 2018 Category: Hematology Authors: Tingting Pan, Jiaqian Qi, Tao You, Liping Yang, Depei Wu, Yue Han, Li Zhu Source Type: research
Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia
We here report a case of acute lymphoblastic B-lineage leukemia (B-ALL) with pseudo Chediak-Higashi (PCH) granules, which represents a rare occurrence in an adult patient. Previously, only few cases, mostly of pediatric age range, have been described in the literature (Table 1). Chediak-Higashi syndrome is a rare autosomal recessive disorder characterized by immunodeficiency, oculocutaneous albinism, neurologic abnormalities and coagulation defects caused by loss of function of the lysosomal trafficking regulator CHS1/LYST gene [1]. (Source: Leukemia Research)
Source: Leukemia Research - June 8, 2018 Category: Hematology Authors: M Gavillet, Spertini Olivier, S Blum Tags: Letter to the Editor Source Type: research
Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
Imatinib (IM) treatment is one of the standards of care for chronic phase (CP) chronic myeloid leukemia (CML). Its generic form is currently widely available as a cost-effective frontline treatment [1]. Although IM treatment has improved outcomes for CML patients, resulting in a 6-year progression-free survival of 93% [2], patients who experience treatment failure at milestones are at increased risk of disease progression to accelerated phase (AP), blast phase (BP), and death due to CML [3 –6]. (Source: Leukemia Research)
Source: Leukemia Research - June 7, 2018 Category: Hematology Authors: Sung-Eun Lee, Soo-Young Choi, Soo-Hyun Kim, Saengsuree Jootar, Hyeoung-Joon Kim, Sang-Kyun Sohn, Joon Seong Park, Sung-Hyun Kim, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim Tags: Research paper Source Type: research
Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study
Myelodysplastic syndromes (MDS) is a heterogeneous group of hematopoietic stem cell disorders that are characterized by cytopenia and dysplastic changes in peripheral blood (PB) and bone marrow (BM) and a propensity to transform into acute myeloid leukemia (AML) [1]. The diagnosis of MDS is based on cytomorphology and cytogenetics. Good cytomorphological experience is required for a correct diagnosis of MDS, particularly lower-risk MDS. The French-American-British (FAB) classification [2] was the standard. (Source: Leukemia Research)
Source: Leukemia Research - June 7, 2018 Category: Hematology Authors: Akira Matsuda, Hiroshi Kawabata, Kaoru Tohyama, Tomoya Maeda, Kayano Araseki, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano, Kei Shimbo, Kensuke Usuki, Shigeru Chiba, Takayuki Ishikawa, Nobuyoshi Arima, Masaharu Nohgawa, Akiko Ohta, Yasushi Miyazaki, Sinn Tags: Research paper Source Type: research
Antimalarial Drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells
Chronic lymphocytic leukemia (CLL) is the most common leukemia and is characterized by the accumulation of monoclonal B cells with typical immunophenotype in peripheral blood, marrow, lymph nodes, and spleen [1]. Patient outcomes are heterogeneous with unmutated status of the immunoglobulin heavy chain variable region (IGHV) and TP53 disruption being important poor prognostic markers. While chemoimmunotherapy remains standard first-line treatment for most patients, the B-cell receptor pathway inhibitors, ibrutinib and idelalisib, or the bcl-2 antagonist, venetoclax, are highly effective in chemotherapy-refractory patients ...
Source: Leukemia Research - June 7, 2018 Category: Hematology Authors: Subhadip Das, Dielschneider Rebecca, Chanas-LaRue Aaron, B. Johnston James, B. Gibson Spencer Tags: Research paper Source Type: research
